Kia's fourth quarter sales were 17.19 trillion won, lower than expected
Kia's fourth quarter sales were 17.19 trillion won, with a market estimate of 17.71 trillion won; The net profit is 1.25 trillion won, and the market estimate is 1.19 trillion won.
This text is a result of machine translation.
Related companies：
Briefing Jun 25, 2022 06:50 AM
In the half year, the 36billion yuan production expansion plan has been thrown away, and the competition in the stock market of Baijiu is fierce
In-depth
Jan 06, 2023 08:30 AM
Nov 16, 2022 05:19 PM
Nov 08, 2022 08:32 AM
Nov 07, 2022 04:27 PM
Briefing Jun 13, 2022 09:44 AM
· Healthcare
Cro plate fell, and Wuxi apptec fell nearly 10%
Healthcare
CRO ClinChoice Raises USD 150 Mn in Series E Round
2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.
Jul 05, 2022 08:17 PM
Healthcare
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Mar 31, 2021 11:38 AM
Briefing Mar 13, 2022 08:49 PM
· Financials
Capital group, an asset management institution, launched ETF products for the first time: buying Chinese stocks such as Guizhou Maotai, Yaoming biology and meituan
See more
Read next